Sign In
Get Clay Free →

Suggestions

    Gilmore ONeill

    Chief Medical Officer at Sarepta Therapeutics

    Gilmore O'Neill is a prominent figure in the biopharmaceutical industry, currently serving as the Chief Executive Officer of Editas Medicine, a position he has held since June 2022. Prior to this role, he was the Executive Vice President of Research and Development and Chief Medical Officer at Sarepta Therapeutics from June 2018 until December 2021. His leadership at Sarepta was marked by overseeing the development of innovative therapies for rare neuromuscular diseases, particularly focusing on Duchenne muscular dystrophy (DMD) .135

    Educational Background

    Dr. O'Neill holds a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard Medical School, specializing in neurology. He also completed his residency in neurology at Massachusetts General Hospital .25

    Career Highlights

    • Sarepta Therapeutics (2018-2021): At Sarepta, Dr. O'Neill was instrumental in leading clinical development and regulatory strategy for several RNA and gene therapeutic programs. His efforts contributed to the advancement of multiple pipeline candidates aimed at treating DMD and other conditions .135
    • Biogen (2003-2018): Before joining Sarepta, he spent over 15 years at Biogen, where he held various senior roles, including Senior Vice President of Late-Stage Clinical Development. He played a key role in the development and approval of significant drugs such as Spinraza® for spinal muscular atrophy and Tecfidera® for multiple sclerosis .234

    Professional Affiliations

    Dr. O'Neill is also involved with several organizations beyond his corporate roles:

    • He serves on the board of directors for UNITY Biotechnology, which focuses on therapeutics for age-related diseases.
    • He is a member of the American Academy of Neurology, reflecting his commitment to advancing neurological health .25

    Vision and Impact

    Throughout his career, Dr. O'Neill has been recognized for his deep expertise in neurobiology and genetic medicine, successfully guiding numerous clinical programs from inception through regulatory approval. His vision is centered on leveraging genetic medicine to improve patient outcomes, particularly for those with rare diseases .135

    Highlights

    Oct 30 · marketscreener.com
    Gilmore O'Neill: Positions, Relations and Network - MarketScreener
    Sep 11 · massbio.org
    Gilmore O'Neill - MassBio
    Gilmore O'Neill - MassBio
    Aug 2 · biotechtv.com
    How a new CEO has been trying to position Editas to execute on the ...
    Aug 4 · Seeking Alpha
    Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha
    Aug 4 · Seeking Alpha
    Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha
    Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - See
    Jun 13 · pharmavoice.com
    First 90 Days: Editas Medicine's Gilmore O'Neill - PharmaVoice
    Apr 14 · biospace.com
    Gilmore O'Neill “Excited” to Take the Reins at Editas Medicine
    Gilmore O'Neill “Excited” to Take the Reins at Editas Medicine
    Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

    Related Questions

    What are Gilmore O'Neill's main responsibilities at Sarepta Therapeutics?
    How did Gilmore O'Neill's role at Biogen prepare him for his position at Sarepta?
    What are some of the key projects Gilmore O'Neill has worked on at Biogen?
    How has Gilmore O'Neill's leadership style impacted Sarepta Therapeutics?
    What are Gilmore O'Neill's educational background and qualifications?
    Gilmore ONeill
    Gilmore ONeill, photo 1
    Gilmore ONeill, photo 2
    Add to my network

    Location

    Greater Boston Area